IBEX 35
11.047,80 -105,20 (-0,94%) Euro Stoxx 50
5.038,17 +22,07 (+0,44%) Dólar/Euro
1,0765 +0,0014 (+0,13%) Petróleo Brent
84,13 +0,55 (+0,66%) Oro
2.335,50 +13,20 (+0,57%) Bitcoin EUR
57.103,45 -715,15 (-1,24%)
Deutsche Biotech Innovativ AG (DBI.F)
Deutsche Biotech Innovativ AG
Neuendorfstrasse 15a
Hennigsdorf 16761
Germany
49 3302 20 77 824
https://www.dbi-ag.de
Sector(es):
Sector:
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Bernd Wegener FRICS | Chairman of Management Board & Chief Executive Officer | N/A | N/A | 1947 |
| Dr. Metod Miklus | COO & Member of Management Board | N/A | N/A | 1959 |
| Dr. Frauke Hein Ph.D. | Chief Business Officer & Head of Business Development | N/A | N/A | N/A |
| Dr. Joachim Struck | Head of Research & Development | N/A | N/A | N/A |
| Dr. Jens Zimmermann | Chief Medical Officer | N/A | N/A | N/A |
Descripción
Deutsche Biotech Innovativ AG operates as a biotechnology company in Germany. The company develops Adrecizumab, an antibody-based therapy that has completed the Phase I/II clinical trial for the treatment of septic shock. It also focuses on the development of various drugs for the treatment of solid tumor, organ failure, rosacea, neurodermatitis, pharyngitis, and Alzheimer's diseases. The company was formerly known as Venetus Beteiligungen AG and changed its name to Deutsche Biotech Innovativ AG in August 2014. Deutsche Biotech Innovativ AG was founded in 2009 and is based in Hennigsdorf, Germany.
Gobierno corporativo
El ISS Governance QualityScore de Deutsche Biotech Innovativ AG, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
